TIDMCOS

Collagen Solutions PLC

11 May 2017

Hardman Research: Trading: earnings above forecasts

Trading update indicates earnings above forecasts - Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced recently to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. The recent trading update for FY 2017 indicated a slight sales shortfall being offset by higher grant income and lower costs, such that the bottom line may well be above market expectations.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/11.05.17-trading-update-indicates-earnings-above-forecasts.pdf?utm_source=Email+Campaign&utm_medium=email&utm_campaign=29208-387733-Collagen%20Solutions%20(COS.L):%20Trading%20update%20indicates%20earnings%20above%20forecasts-Preview

 
 To contact us:      Contacts: 
  Hardman & Co        Dr Martin Hall 
  11/12 Tokenhouse    mh@hardmanandco.com 
  Yard                Dr Dorothea Hill 
  London              dmh@hardmanandco.com 
  EC2R 7AS            Dr Gregoire Pave 
                      gp@hardmanabdco.com 
                      Telephone: +44 20 7929 3399 
                      Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABLGDUCGBBGRG

(END) Dow Jones Newswires

May 11, 2017 02:15 ET (06:15 GMT)

Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Healthcare Inv Charts.
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Healthcare Inv Charts.